美女免费一级视频在线观看

    1. <form id=BiMYPaeIF><nobr id=BiMYPaeIF></nobr></form>
      <address id=BiMYPaeIF><nobr id=BiMYPaeIF><nobr id=BiMYPaeIF></nobr></nobr></address>

      AstraZeneca’s intranasal, needle-free vaccine FluMist has been around for more than two decades but now it’s available for people to use in the comfort of their own homes.

      On Friday morning, the British pharma giant launched the at-home version of FluMist for patients between the ages of 18 and 49 to self-administer and for caregivers of minors between the ages of two and 17.

      The at-home version of FluMist was approved by the Food and Drug Administration in September 2024.

      Now, the vaccine is available through FluMist.com for the 2025-2026 flu season in 34 states, as a number of states don’t allow FluMist Home due to local pharmacy laws.

      Patients can visit the website, complete a screening questionnaire reviewed by a licensed healthcare provider employed by ASPN Pharmacies and have the vaccine shipped directly to their home.

      The vaccines are delivered by Polaris Pharmacy Services in cold-chain shipments and seek to address barriers like trypanophobia – the fear of needles – to make flu shot options more convenient.

      Updated by text message, users are provided with storage guidance and can dispose of the vaccine properly, with a prepaid envelope included in the order.

      In response to market research, AstraZeneca’s FluMist Home was designed to boost low flu vaccination rates by providing an easy, at-home option to patients.

      According to data from the Centers for Disease Control and Prevention, the flu vaccination rate among adults was 44.9% in the 2023-24 flu season – down two percentage points from the prior season.

      Liz Bodin, AstraZeneca’s VP of U.S. respiratory and immunology, vaccines and immune therapies, said the drugmaker’s efforts align with the post-pandemic trend of people embracing remote healthcare access.

      “We know there’s a population of patients who lead busy lives and sometimes just the task of going to the clinic, the pharmacy or their physician to get a vaccination can be one of the barriers to care,” she said. 

      AstraZeneca is supporting the product launch with a campaign, highlighted by a minute-long ad targeting busy caregivers and families.

      FluMist Home was designed to be intuitive and consumer-friendly, as demonstrated by the commercial.

      The pharma giant is also providing easy-to-use instructions and videos to guide patients on the at-home administration process.

      Through its marketing efforts, AstraZeneca is seeking to empower patients by positioning the shot as one that they can administer at home without needing to visit a pharmacy.

      With support from agency partner Edelman, the company is leveraging digital outreach and in-person events to promote the effort. 

      To achieve the greatest impact, AstraZeneca is leveraging trusted voices like medical experts, patient advocacy groups and HCPs to educate and reassure the public about the vaccine’s safety and efficacy.

      This FluMist Home launch comes a few months ahead of the start of the 2025-26 flu season and on the heels of the 2024-25 flu season, which was the worst flu season since the H1N1 pandemic of 2009.

      Since flu vaccination rates have decreased below pre-pandemic levels, Bodin emphasized the need for a different approach to promote the shots among the general public.

      Data indicates that flu vaccination rates have declined across the board, especially among children and adults under 50 – with the lowest rates among adults aged 18 to 49.

      By embracing this new modality with FluMist Home, Bodin said the company is seeking to make the flu vaccine more convenient for patients.

      FluMist Home, she added, is expected to complement the efforts of HCPs immunizing patients against the influenza virus.

      “We need to reach our target audience of busy caregivers and families [to let them know] that the convenience coupled with the safety and efficacy of FluMist Home is an option,” she said. 

      Related: In AstraZeneca’s DTC spot, Tagrisso breathes new life into lung cancer treatment

      Related: Watch the FluMist ad that received an FDA warning letter following Trump’s memo